HomeNDC LookupIngredientsDesonide › 62332-0632-60
Desonide .5 mg/g Cream — NDC 62332-0632-60 package photo

Desonide .5 mg/g Cream

by Alembic Pharmaceuticals Inc. · 1 TUBE in 1 CARTON (62332-632-60) / 60 g in 1 TUBE
NDC 62332-0632-60
🏷️ FDA NDC (as labeled) 62332-632-60 billing pads the product segment with a zero
This package
Contains60 g in 1 tube Cost per g$0.1996 NADAC Per package$11.98 / 60 g Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.4846/unit · Part D plans $0.6421/unit — full pricing hub ↓
Also comes in: 15 g 62332-0632-15
Rx only Generic On market Non-controlled
🗂️ Data synced Aug 6, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 62332-632-60
Product NDC 62332-632
11-digit billing NDC 62332063260
NCPDP billing unit GM — per gram (weight)
RxCUI 349351
UNII J280872D1O
UPC 0362332632152, 0362332632602
Application # ANDA214396
SPL Set ID c3420815-e9d8-4c19-b601-b918b0aa1f84
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2022-12-08
Route TOPICAL
Dosage form CREAM
Substance DESONIDE
GCN Seq No 007620
GCN 31425
HICL code 003322
Ingredient (HICL) Desonide
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5P
Therapeutic class — specific (HIC3) Topical Anti-Inflammatory Steroidal
AHFS code 84:06.08.00
AHFS class Corticosteroids (Skin, Mucous Membrane)
FDB label name DESONIDE 0.05% CREAM
FDB brand name Desonide
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 62332-632-60 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 62332-0632-60. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids, moderately potent (group II), Corticosteroids, plain
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerAlembic Pharmaceuticals Inc.
Application holderALEMBIC PHARMACEUTICALS LTD
FDA applicationANDA214396 (ANDA)
Labeler code62332
First marketedDec 2022
Product typeHuman Prescription Drug
Portfolio491 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name DESONIDE 0.05% CREAM Ingredient Desonide
📗 Our plain-language guide HelloPharmacist
  • Desonide is a mild topical steroid used to calm inflamed, itchy skin. Desonide gel is specifically approved for mild to moderate atopic dermatitis — commonly called eczema — in bab...
  • What skin problems is desonide actually used for?
  • Apply a thin layer to the affected skin only — you don't need a thick coat. The gel is typically used twice a day; the cream or ointment may be used two to four times a day dependi...
  • Desonide is meant to be used for the shortest time needed to get your skin under control. The gel form should not be used for more than 4 consecutive weeks. The cream and ointment...
📖 Read our full Desonide guide →

Supplement & herbal interactions

Some supplements/herbs that may interact with Desonide — tap one for details:

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 34S289N54E
    Aluminum sulfate is a salt compound used in medicines as an astringent and buffering agent. It helps regulate acidity and can be used in topical or oral formulations to reduce moisture and control pH levels.
  • UNII Y882YXF34X
    Calcium acetate is a mineral salt made from calcium and acetic acid. In medicines, it acts as a binder to hold ingredients together and can help control the acidity level of the formulation.
  • UNII 2DMT128M1S
    A waxy solid derived from plant or animal sources. It acts as an emulsifier to blend oil and water components, and also thickens the medicine to give it the right texture and consistency.
  • UNII 7FLD91C86K
    Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 2NX48Z0A9G
    Icodextrin is a glucose polymer derived from starch. It acts as a thickening agent and osmotic agent in medicines, helping to control texture and absorption in formulations like eye drops or injectable solutions.
  • UNII N6K5787QVP
    Light mineral oil is a clear, odorless liquid derived from petroleum. In medicines, it acts as a lubricant and emollient to help the product spread smoothly and improve texture.
  • UNII 4T6H12BN9U
    Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.
  • UNII 368GB5141J
    A detergent and foaming agent derived from coconut or palm oil. In medications, it helps break down and mix oil and water-based ingredients, aids in tablet disintegration, and improves how the drug dissolves and spreads in the mouth or digestive system.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
  • UNII 7G1J5DA97F
    White wax is a refined, bleached plant-based or mineral wax that serves as a coating and hardening agent in medicines. It helps control how fast the drug dissolves and improves the product's texture and appearance.

11 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.200 $11.98 / 60 g
Medicaid paysCMS SDUD · 12 mo $0.4846 $29.08 / 60 g
Medicare drug plans payPart D · Q2 2026 $0.6421 $38.53 / 60 g
NADAC price history (per g) — tap or hover for the price & month
Dec 2023 Dec 2025 Apr 2026 Aug 2026 $0.372 $0.189
▼ Down 46% over the last 12 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Desonide .5 mg/gthis 62332-0632-60 Alembic 1 tube $0.200 AB Availability likely
Desonide .5 mg/g 00472-0804-15 Actavis 1 tube $0.266 AB Discontinued +33%
Desonide .5 mg/g 00713-0661-15 Cosette 1 tube $0.302 AB Availability likely +52%
Desonide .5 mg/g 16714-0729-01 NORTHSTAR 1 tube $0.302 AB Availability likely +52%
Desonide .5 mg/g 51672-1280-01 Sun 1 tube $0.302 AB Availability likely +52%
Desonide .5 mg/g 72578-0086-01 Viona 1 tube $0.302 AB Availability likely +52%
Desonide .5 mg/g 45802-0423-35 Padagis 1 tube $0.410 AB Availability likely +105%
Desonide .5 mg/g 72603-0164-01 NORTHSTAR 1 tube $0.410 AB Availability likely +105%
Desonide .5 mg/g 51672-1281-01 Sun 1 tube $0.410 AB Availability likely +105%
Desonide .5 mg/g 62332-0485-15 Alembic 1 tube $0.410 AB Availability likely +105%
Desonide .5 mg/g 46708-0632-15 Alembic 1 tube AB FDA listed
Desonide .5 mg/g 63187-0747-15 Proficient 1 tube AB FDA listed
Desonide .5 mg/g 63629-2506-01 Bryant 1 tube AB FDA listed
Desonide .5 mg/g 63629-2507-01 Bryant 1 tube AB FDA listed
Tridesilon Cream .03 g/60g 69482-0600-60 Encore 1 tube FDA listed
Desonide .5 mg/g 70771-1381-01 Zydus 1 tube AB FDA listed
Desonide .5 mg/g 72162-2005-02 Bryant 1 tube AB FDA listed
Desonide .5 mg/g 80425-0371-01 Advanced 1 tube AB FDA listed
Desonide .5 mg/g 80425-0418-01 Advanced 1 tube AB FDA listed
Desonide .5 mg/g 24470-0920-60 Cintex 1 tube FDA listed
Desonide .5 mg/g 46708-0485-15 Alembic 1 tube AB FDA listed
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2022
On the market since
Dec 2022
📍
2026
Currently FDA-listed
4 years listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 62332-0632-60, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
1.7K
Units reimbursed last 4 qtrs
105.2K
Gross reimbursed last 4 qtrs
$51K
Avg / prescription
$29.92
Avg / unit
$0.4846
Latest quarter Q4 2025
428Rx
Medicaid pays / g
$0.4846
gross reimbursed
vs
NADAC / g
$0.1996
acquisition cost
=
Spread
+$0.2850
+143% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
45% FFS 55% MCO
Fee-for-service · 759 Rx Managed care · 945 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 8,220 units · 105 per 100k residents WA Idaho: 855 units · 43.5 per 100k residents ID Montana: no data reported MT North Dakota: 1,800 units · 230 per 100k residents ND Minnesota: 4,680 units · 81.6 per 100k residents MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 14,250 units · 72.8 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 3,480 units · 27.7 per 100k residents IL Indiana: no data reported IN Ohio: 11,070 units · 93.9 per 100k residents OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: 19,320 units · 49.6 per 100k residents CA Utah: 660 units · 19.3 per 100k residents UT Colorado: 540 units · 9.2 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 5,940 units · 131 per 100k residents KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: 5,025 units · 81.3 per 100k residents MD Connecticut: 2,340 units · 64.7 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 840 units · 11.8 per 100k residents TN North Carolina: 7,594 units · 70.1 per 100k residents NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: 4,200 units · 143 per 100k residents MS Alabama: 6,660 units · 130 per 100k residents AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 7,740 units · 25.4 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
9.2230
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 North Dakota 230 /100k
2 Mississippi 143 /100k
3 Kentucky 131 /100k
4 Alabama 130 /100k
5 Washington 105 /100k
6 Ohio 93.9 /100k
7 Minnesota 81.6 /100k
8 Maryland 81.3 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube this page62332-0632-60 1,704 Rx · $50,984
1 tube62332-0632-15 1,250 Rx · $22,315
Drug total (last 4 qtrs): 2,954 Rx · 135,064 units · $73,299 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Desonide — the program that covers self-administered drugs. 9 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Desonide. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$2.45M
Claims incl. refills
55.6K
Beneficiaries
48.4K
Spend / beneficiary
$50.71
Spend / claim
$44.15
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Desonide — the ingredient across all brands.

Top reported reactions

Macular Degeneration787
Pain392
Nausea376
Pruritus345
Rash327
Headache322
Erythema316

Reporter sex

4,959 reports
Male · 35%
Female · 64%
Unknown · 0%

Serious outcomes

Death196
Disabling91
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 620 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
62332-0632-15 1 TUBE in 1 CARTON (62332-632-15) / 15 g in 1 TUBE $0.3025 / g $4.54 2022-12-08 Active
62332-0632-60 You're viewing this 1 TUBE in 1 CARTON (62332-632-60) / 60 g in 1 TUBE $0.1996 / g $11.98 2022-12-08 Active

This pack has the lowest per-g cost of the 2 priced pack sizes ($0.1996 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 58% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in NDC 62332-0632-60?
NDC 62332-0632-60 is listed by the FDA — 1 tube in 1 carton / 60 g in 1 tube.
What NDC number is used to bill for this package of Desonide .5 mg/g Cream?
Bill NDC 62332-0632-60 — the 11-digit billing format is 62332063260. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 41 words

INDICATIONS AND USAGE Desonide cream USP, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.

⏱️ Dosage and Administration 67 words

DOSAGE AND ADMINISTRATION Desonide cream USP, 0.05% should be applied to the affected area as a thin film two to four times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Desonide cream USP, 0.05% should not be used with occlusive dressings.

Contraindications 23 words

CONTRAINDICATIONS Desonide cream USP, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

🤒 Adverse Reactions 116 words

ADVERSE REACTIONS In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide cream USP, 0.05% was approximately 1%. These adverse reactions were pruritus, pain, folliculitis, rash, peripheral edema, pustular rash, sweating, erythema, irritation, and burning. Laboratory abnormalities were found in 3% of the patients.

These were hyperglycemia (2%) and liver function abnormality (1%). The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation.

🆘 Overdosage 20 words

OVERDOSAGE Topically applied desonide cream USP, 0.05% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).

🧬 Clinical Pharmacology 181 words

CLINICAL PHARMACOLOGY Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins.

It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2 . Pharmacokinetics - The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier.

Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.

Studies performed with desonide cream USP, 0.05% indicate that it is in the low range of potency as compared with other topical corticosteroids.

📦 How Supplied / Storage and Handling 25 words

HOW SUPPLIED Desonide cream USP, 0.05% is white to off white cream available as follows: 15 g tube (NDC 62332-632-15) 60 g tube (NDC 62332-632-60)

📦 Storage and Handling 49 words

STORAGE Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Manufactured for: Alembic Pharmaceuticals, Inc. Bedminster, NJ 07921, USA Manufactured by: Alembic Pharmaceuticals Limited (Derma Division), Karakhadi, Vadodara 391450, India. Mfg. License No.: G/25/2216 Revised: 8/2025

📋 Description 141 words

DESCRIPTION Desonide cream USP, 0.05% contains desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11β,16α)) a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primary synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, desonide, the active ingredient in desonide cream USP, 0.05% is C 24 H 32 O 6 .

It has the following structural formula: The molecular weight of desonide is 416.51. It is a white to almost white crystalline powder. The solubility of desonide in distilled water saturated with ether is 184 mg/L.

Each gram of desonide cream USP, 0.05% contains 0.5 mg of desonide, USP microdispersed in a base of aluminum sulfate, calcium acetate, cetostearyl alcohol, dextrin, edetate disodium, glycerin, light mineral oil, purified water, sodium lauryl sulfate, white wax, and white petrolatum. Desonide cream USP, 0.05% is preserved with methylparaben and buffered to pH 4.2 to 5.0. Image

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.